Pyxis Oncology (PYXS) Income from Continuing Operations (2020 - 2025)
Pyxis Oncology's (PYXS) quarterly Income from Continuing Operations came in at 18389000.0 in Q4 2025, up 48.3% year-on-year from 12399581.43 in Q4 2024, and up 16.43% on a QoQ basis from 22003000.0 in Q3 2025.
Pyxis Oncology (PYXS) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Income from Continuing Operations data on file, last reported at 18389000.0 in Q4 2025.
- On a quarterly basis, Income from Continuing Operations rose 48.3% year-over-year to 18389000.0 in Q4 2025; TTM through Dec 2025 was 81303000.0, a 5.25% increase from a year earlier, with the FY2025 full-year figure at 79621000.0, down 2.96% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 18389000.0, up from 22003000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PYXS reached as high as 5935000.0 in Q2 2021 and fell as low as 46370000.0 in Q3 2021.
- Historically, Income from Continuing Operations has averaged 26009000.0 across 5 years, with a median of 23272000.0 in 2023.
- Across the five-year window, Income from Continuing Operations plunged 1353.15% in 2021 and jumped 54.22% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 32833000.0 in 2021, then retreated by 8.01% to 35464000.0 in 2022, then jumped by 50.45% to 17573000.0 in 2023, then slumped by 102.42% to 35571000.0 in 2024, then jumped by 48.3% to 18389000.0 in 2025.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 18389000.0 in Q4 2025, 22003000.0 in Q3 2025, and 18354000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn | -18.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.39 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Jun 30, 2025 | -18.35 Mn |
| Mar 31, 2025 | -22.56 Mn |
| Dec 31, 2024 | -35.57 Mn |
| Sep 30, 2024 | -21.20 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -11.73 Mn |
| Dec 31, 2023 | -17.57 Mn |
| Sep 30, 2023 | -23.99 Mn |
| Jun 30, 2023 | -17.90 Mn |
| Mar 31, 2023 | -25.63 Mn |
| Dec 31, 2022 | -35.46 Mn |
| Sep 30, 2022 | -40.79 Mn |
| Jun 30, 2022 | -39.05 Mn |
| Mar 31, 2022 | -31.82 Mn |
| Dec 31, 2021 | -32.83 Mn |
| Sep 30, 2021 | -46.37 Mn |
| Jun 30, 2021 | -5.94 Mn |
| Mar 31, 2021 | -35.73 Mn |